FDA OKs Velcade for priority review

The FDA on Wednesday granted priority review for the use of injectable myeloma drug Velcade in patients with newly diagnosed multiple myeloma, Cambridge, Mass.-based Millennium Pharmaceuticals announced. The drug, approved to treat multiple myeloma or mantle cell lymphoma in patients who have already received other therapies, is being tested as a first-line treatment for the blood cancer.

View Full Article in:

American City Business Journals · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC